share_log

Medtronic | 8-K: Current report

Medtronic | 8-K: Current report

美敦力 | 8-K：重大事件
美股SEC公告 ·  2024/08/20 18:49

Moomoo AI 已提取核心訊息

Medtronic reported Q1 FY25 revenue of $7.9 billion, increasing 2.8% as reported and 5.3% organic. GAAP diluted EPS rose 36% to $0.80, while non-GAAP diluted EPS grew 3% to $1.23. Growth was driven by strong performance across multiple franchises, including Cardiac Ablation Solutions, Neuromodulation, Spine, Structural Heart, and Diabetes.The Cardiovascular Portfolio led growth with 6.9% organic increase, followed by Neuroscience at 5.3% and Diabetes at 12.6%. Notable product innovations included the PulseSelect pulsed field ablation system, Evolut FX+ TAVR system, and MiniMed 780G automated insulin delivery system. The U.S. Diabetes segment showed particular strength with mid-teens growth.Based on strong Q1 performance, Medtronic raised its FY25 guidance, projecting organic revenue growth of 4.5-5% (up from 4-5%) and non-GAAP diluted EPS of $5.42-$5.50 (previously $5.40-$5.50). The company expects sustained growth from new product introductions while continuing strategic investments to support launches.
Medtronic reported Q1 FY25 revenue of $7.9 billion, increasing 2.8% as reported and 5.3% organic. GAAP diluted EPS rose 36% to $0.80, while non-GAAP diluted EPS grew 3% to $1.23. Growth was driven by strong performance across multiple franchises, including Cardiac Ablation Solutions, Neuromodulation, Spine, Structural Heart, and Diabetes.The Cardiovascular Portfolio led growth with 6.9% organic increase, followed by Neuroscience at 5.3% and Diabetes at 12.6%. Notable product innovations included the PulseSelect pulsed field ablation system, Evolut FX+ TAVR system, and MiniMed 780G automated insulin delivery system. The U.S. Diabetes segment showed particular strength with mid-teens growth.Based on strong Q1 performance, Medtronic raised its FY25 guidance, projecting organic revenue growth of 4.5-5% (up from 4-5%) and non-GAAP diluted EPS of $5.42-$5.50 (previously $5.40-$5.50). The company expects sustained growth from new product introductions while continuing strategic investments to support launches.
美敦力報告稱2025財年第一季度營業收入爲79億，報告增長2.8%，有機增長5.3%。根據美國通用會計準則（GAAP）攤薄後每股收益上升36%，達到0.80美元，而非GAAP攤薄後每股收益增長3%，達到1.23美元。增長得益於多個業務領域的強勁表現，包括心臟消融解決方案、神經調節、脊柱、結構性心臟和糖尿病。心血管產品組合引領增長，有機增長6.9%，神經科學增長5.3%，糖尿病增長12.6%。值得注意的產品創新包括PulseSelect脈衝場消融系統、Evolut FX+經導管主動脈瓣置換（TAVR）系統和MiniMed 780G自動胰島素輸送系統。美國糖尿病業務部門表現尤其強勁，增長中段達到兩...展開全部
美敦力報告稱2025財年第一季度營業收入爲79億，報告增長2.8%，有機增長5.3%。根據美國通用會計準則（GAAP）攤薄後每股收益上升36%，達到0.80美元，而非GAAP攤薄後每股收益增長3%，達到1.23美元。增長得益於多個業務領域的強勁表現，包括心臟消融解決方案、神經調節、脊柱、結構性心臟和糖尿病。心血管產品組合引領增長，有機增長6.9%，神經科學增長5.3%，糖尿病增長12.6%。值得注意的產品創新包括PulseSelect脈衝場消融系統、Evolut FX+經導管主動脈瓣置換（TAVR）系統和MiniMed 780G自動胰島素輸送系統。美國糖尿病業務部門表現尤其強勁，增長中段達到兩位數。基於強勁的第一季度表現，美敦力提升了2025財年指導，預計有機營業收入增長爲4.5%-5%（從4%-5%上調）和非GAAP攤薄後每股收益爲5.42美元-5.50美元（之前爲5.40美元-5.50美元）。公司預計將從新產品的推出中持續增長，同時繼續進行戰略投資以支持產品發佈。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    PAVmed
    PAVMZ
    -- 0.0162
    Allurion Technologies
    ALUR
    -- 3.700
    Baird Medical Investment Holdings
    BDMD
    -- 8.150
    Adagio Medical
    ADGM
    -- 0.921
    Bluejay Diagnostics
    BJDX
    -- 4.0000
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    科技巨頭業績季拉開帷幕： 市場將如何反應？
    🎙️ 討論： 1. 大型科技公司的業績能否再次引領各版塊上漲？ 2. 科技巨頭將會如何受到「特朗普因素」的影響？ 展开
    在科技巨頭公佈業績之前，您需要了解的情況